In‐vivo quality assurance of dynamic tumor tracking (DTT) for liver SABR using EPID images
Journal of Applied Clinical Medical Physics · 2023
DOI: 10.1002/acm2.13969 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Clinical Medical Physics, 2023. Verfasst von Maryam Rostamzadeh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Radiotherapy, Conformal, Neoplasms, Radiosurgery. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To assess dynamic tumor tracking (DTT) target localization uncertainty for in‐vivo marker‐based stereotactic ablative radiotherapy (SABR) treatments of the liver using electronic‐portal‐imaging‐device (EPID) images. The Planning Target Volume (PTV) margin contribution for DTT is estimated.
Methods
Phantom and patient EPID images were acquired during non‐coplanar 3DCRT‐DTT delivered on a Vero4DRT linac. A chain‐code algorithm was applied to detect Multileaf Collimator (MLC)‐defined radiation field edges. Gold‐seed markers were detected using a connected neighbor algorithm. For each EPID image, the absolute differences between the measured center‐of‐mass (COM) of the markers relative to the aperture‐center (Tracking Error, (E T )) was reported in pan, tilt, and 2D‐vector directions at the isocenter‐plane. Phantom study An acrylic cube phantom implanted with gold‐seed markers was irradiated with non‐coplanar 3DCRT‐DTT beams and EPID images collected. Patient Study : Eight liver SABR patients were treated with non‐coplanar 3DCRT‐DTT beams. All patients had three to four implanted gold‐markers. In‐vivo EPID images were analyzed.
Results
Phantom Study : On the 125 EPID images collected, 100% of the markers were identified. The average ± SD of E T were 0.24 ± 0.21, 0.47 ± 0.38, and 0.58 ± 0.37 mm in pan, tilt and 2D directions, respectively. Patient Study : Of the 1430 EPID patient images acquired, 78% had detectable markers. Over all patients, the average ± SD of E T was 0.33 ± 0.41 mm in pan, 0.63 ± 0.75 mm in tilt and 0.77 ± 0.80 mm in 2D directions The random 2D‐error, σ, for all patients was 0.79 mm and the systematic 2D‐error, Σ, was 0.20 mm. Using the Van Herk margin formula 1.1 mm planning target margin can represent the marker based DTT uncertainty.
Conclusions
Marker‐based DTT uncertainty can be evaluated in‐vivo on a field‐by‐field basis using EPID images. This information can contribute to PTV margin calculations for DTT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada.
- Medical Physics Department, BC Cancer-Vancouver, Vancouver, Canada.
- Radiation Oncology Department, BC Cancer-Vancouver, Vancouver, Canada.
ORCID-Profile: Tania Karan, Alanah Bergman
Zitieren
APA
Rostamzadeh, M., Luchka, K., Ma, R., Liu, M., Dunne, E., Camborde, M. L., Karan, T., Mestrovic, A., & Bergman, A. (2023). In‐vivo quality assurance of dynamic tumor tracking (DTT) for liver SABR using EPID images. Journal of Applied Clinical Medical Physics. https://doi.org/10.1002/acm2.13969
Vancouver
Rostamzadeh M, Luchka K, Ma R, Liu M, Dunne E, Camborde ML, et al. In‐vivo quality assurance of dynamic tumor tracking (DTT) for liver SABR using EPID images. Journal of Applied Clinical Medical Physics. 2023. doi:10.1002/acm2.13969
BibTeX
@article{Rostamzadeh2023,
author = {Rostamzadeh, Maryam and Luchka, Kurt and Ma, Roy and Liu, Mitchell and Dunne, Emma and Camborde, Marie-Laure and Karan, Tania and Mestrovic, Ante and Bergman, Alanah},
title = {In‐vivo quality assurance of dynamic tumor tracking (DTT) for liver SABR using EPID images},
journal = {Journal of Applied Clinical Medical Physics},
year = {2023},
doi = {10.1002/acm2.13969}
}
EUVIMED